Symbols / NVCR
NVCR Chart
About
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 1.53B |
| Enterprise Value | 1.35B | Income | -136.23M | Sales | 655.35M |
| Book/sh | 3.03 | Cash/sh | 3.93 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -12.50 | PEG | — |
| P/S | 2.34 | P/B | 4.52 | P/C | — |
| EV/EBITDA | -9.73 | EV/Sales | 2.07 | Quick Ratio | 2.67 |
| Current Ratio | 2.90 | Debt/Eq | 69.52 | LT Debt/Eq | — |
| EPS (ttm) | -1.61 | EPS next Y | -1.09 | EPS Growth | — |
| Revenue Growth | 8.10% | Earnings | 2026-04-23 | ROA | -9.40% |
| ROE | -38.89% | ROIC | — | Gross Margin | 74.54% |
| Oper. Margin | -24.49% | Profit Margin | -20.79% | Shs Outstand | 111.98M |
| Shs Float | 94.01M | Short Float | 12.54% | Short Ratio | 3.98 |
| Short Interest | — | 52W High | 21.55 | 52W Low | 9.82 |
| Beta | — | Avg Volume | 2.02M | Volume | 2.51M |
| Target Price | $25.93 | Recom | Buy | Prev Close | $13.75 |
| Price | $13.67 | Change | -0.58% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.93
Mean price target
2. Current target
$13.67
Latest analyst target
3. DCF / Fair value
$-20.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.67
Low
$13.50
High
$49.00
Mean
$25.93
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | HC Wainwright & Co. | Buy → Buy | $49 |
| 2026-02-12 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2026-01-15 | reit | Wedbush | Neutral → Neutral | $18 |
| 2026-01-13 | main | HC Wainwright & Co. | Buy → Buy | $39 |
| 2025-10-30 | main | HC Wainwright & Co. | Buy → Buy | $42 |
| 2025-10-27 | main | JP Morgan | Neutral → Neutral | $23 |
| 2025-07-25 | down | Wells Fargo | Overweight → Equal-Weight | $15 |
| 2025-07-08 | init | Ladenburg Thalmann | — → Buy | $30 |
| 2025-06-27 | reit | Piper Sandler | Overweight → Overweight | $34 |
| 2025-04-23 | main | Piper Sandler | Overweight → Overweight | $34 |
| 2025-04-16 | main | Wedbush | Neutral → Neutral | $27 |
| 2025-04-10 | main | JP Morgan | Neutral → Neutral | $28 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-12-13 | main | Piper Sandler | Overweight → Overweight | $42 |
| 2024-12-03 | main | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
| 2024-12-02 | up | Evercore ISI Group | In-Line → Outperform | $30 |
| 2024-11-21 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-16 | up | HC Wainwright & Co. | Neutral → Buy | $30 |
- $NVCR stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 25 Feb 2026 14
- NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat Fri, 27 Feb 2026 04
- NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 17
- BC becomes first province to fund Novocure brain cancer therapy - Stock Titan ue, 24 Feb 2026 12
- What’s Happening With NovoCure Stock? - Forbes hu, 12 Feb 2026 08
- HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $49 | - GuruFocus hu, 26 Feb 2026 19
- (NVCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily hu, 26 Feb 2026 11
- NovoCure (NVCR) Q4 Loss Narrowing Challenges Bearish Narrative On Persistent Unprofitability - simplywall.st Fri, 27 Feb 2026 01
- NOVOCURE ($NVCR) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 13
- Novocure shares surge after FDA approves Optune Pax for pancreatic cancer (NVCR:NASDAQ) - Seeking Alpha hu, 12 Feb 2026 08
- NovoCure (NASDAQ:NVCR) Shares Gap Down - What's Next? - MarketBeat hu, 26 Feb 2026 17
- Interesting NVCR Put And Call Options For April 17th - Nasdaq ue, 24 Feb 2026 15
- NovoCure (NASDAQ:NVCR) Shares Gap Up - Should You Buy? - MarketBeat Wed, 25 Feb 2026 18
- $NVCR stock is up 35% today. Here's what we see in our data. - Quiver Quantitative hu, 12 Feb 2026 08
- Assessing NovoCure (NVCR) Valuation After British Columbia’s Reimbursement Breakthrough for TTFields Therapy - simplywall.st Wed, 25 Feb 2026 19
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 11 | — | Stock Award(Grant) at price 10.99 per share. | DANZIGER ASAF | Director | — | 2025-12-31 00:00:00 | D |
| 1 | 108 | 1187 | — | Stock Award(Grant) at price 10.99 per share. | BEN ARYE BARAK | General Counsel | — | 2025-12-31 00:00:00 | D |
| 2 | 1 | 11 | — | Stock Award(Grant) at price 10.99 per share. | PURI MICHAL NATH | Officer | — | 2025-12-31 00:00:00 | D |
| 3 | 81550 | 996859 | — | Purchase at price 12.22 per share. | CORDOVA ASHLEY | Chief Executive Officer | — | 2025-09-05 00:00:00 | D |
| 4 | 20000 | 231800 | — | Purchase at price 11.50 - 11.63 per share. | BRACKMANN CHRISTOPH | Chief Financial Officer | — | 2025-07-29 00:00:00 | D |
| 5 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | DANZIGER ASAF | Director | — | 2025-06-30 00:00:00 | D |
| 6 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | LEONARD FRANCIS XAVIER II | Officer | — | 2025-06-30 00:00:00 | D |
| 7 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | CORDOVA ASHLEY | Chief Executive Officer | — | 2025-06-30 00:00:00 | D |
| 8 | 769 | 11635 | — | Stock Award(Grant) at price 15.13 per share. | BEN ARYE BARAK | General Counsel | — | 2025-06-30 00:00:00 | D |
| 9 | 833 | 12603 | — | Stock Award(Grant) at price 15.13 per share. | PURI MICHAL NATH | Officer | — | 2025-06-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -150.57K | -167.37K | -739.83K | -1.09M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -108.87M | -176.66M | -64.36M | -34.35M |
| TotalUnusualItems | -717.00K | -797.00K | -3.52M | -4.03M |
| TotalUnusualItemsExcludingGoodwill | -717.00K | -797.00K | -3.52M | -4.03M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -168.63M | -207.04M | -92.53M | -58.35M |
| ReconciledDepreciation | 11.23M | 10.97M | 10.62M | 10.25M |
| ReconciledCostOfRevenue | 137.18M | 128.28M | 114.87M | 114.88M |
| EBITDA | -109.58M | -177.45M | -67.89M | -38.38M |
| EBIT | -120.82M | -188.42M | -78.51M | -48.63M |
| NetInterestIncome | 40.05M | 41.93M | 11.20M | -3.71M |
| InterestExpense | 10.34M | 3.32M | 3.33M | 3.44M |
| InterestIncome | 22.72M | 19.64M | 10.96M | 791.00K |
| NormalizedIncome | -168.06M | -206.41M | -89.75M | -55.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -168.63M | -207.04M | -92.53M | -58.35M |
| TotalExpenses | 775.72M | 742.21M | 627.36M | 579.36M |
| TotalOperatingIncomeAsReported | -170.50M | -232.87M | -89.52M | -44.33M |
| DilutedAverageShares | 107.83M | 106.39M | 104.66M | 103.43M |
| BasicAverageShares | 107.83M | 106.39M | 104.66M | 103.43M |
| DilutedEPS | -1.56 | -1.95 | -0.88 | -0.56 |
| BasicEPS | -1.56 | -1.95 | -0.88 | -0.56 |
| DilutedNIAvailtoComStockholders | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncomeCommonStockholders | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncome | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncomeIncludingNoncontrollingInterests | -168.63M | -207.04M | -92.53M | -58.35M |
| NetIncomeContinuousOperations | -168.63M | -207.04M | -92.53M | -58.35M |
| TaxProvision | 37.47M | 15.30M | 10.69M | 6.28M |
| PretaxIncome | -131.16M | -191.74M | -81.85M | -52.08M |
| OtherIncomeExpense | -717.00K | -797.00K | -3.52M | -4.03M |
| GainOnSaleOfSecurity | -717.00K | -797.00K | -3.52M | -4.03M |
| NetNonOperatingInterestIncomeExpense | 40.05M | 41.93M | 11.20M | -3.71M |
| TotalOtherFinanceCost | -27.67M | -25.61M | -3.57M | 1.06M |
| InterestExpenseNonOperating | 10.34M | 3.32M | 3.33M | 3.44M |
| InterestIncomeNonOperating | 22.72M | 19.64M | 10.96M | 791.00K |
| OperatingIncome | -170.50M | -232.87M | -89.52M | -44.33M |
| OperatingExpense | 638.53M | 613.93M | 512.50M | 464.49M |
| ResearchAndDevelopment | 209.65M | 223.06M | 206.09M | 201.30M |
| SellingGeneralAndAdministration | 428.89M | 390.87M | 306.41M | 263.18M |
| SellingAndMarketingExpense | 239.06M | 226.81M | 173.66M | 137.06M |
| GeneralAndAdministrativeExpense | 189.83M | 164.06M | 132.75M | 126.13M |
| OtherGandA | 189.83M | 164.06M | 132.75M | 126.13M |
| GrossProfit | 468.04M | 381.06M | 422.97M | 420.15M |
| CostOfRevenue | 137.18M | 128.28M | 114.87M | 114.88M |
| TotalRevenue | 605.22M | 509.34M | 537.84M | 535.03M |
| OperatingRevenue | 605.22M | 509.34M | 537.84M | 535.03M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 108.52M | 107.08M | 105.05M | 103.97M |
| ShareIssued | 108.52M | 107.08M | 105.05M | 103.97M |
| NetDebt | 491.69M | 328.00M | 450.18M | 353.41M |
| TotalDebt | 683.35M | 604.56M | 584.27M | 575.21M |
| TangibleBookValue | 360.18M | 362.50M | 441.17M | 410.49M |
| InvestedCapital | 1.02B | 931.32M | 1.01B | 972.71M |
| WorkingCapital | 350.20M | 855.29M | 952.75M | 930.92M |
| NetTangibleAssets | 360.18M | 362.50M | 441.17M | 410.49M |
| CapitalLeaseObligations | 27.89M | 35.74M | 18.76M | 13.00M |
| CommonStockEquity | 360.18M | 362.50M | 441.17M | 410.49M |
| TotalCapitalization | 457.48M | 931.32M | 1.01B | 972.71M |
| TotalEquityGrossMinorityInterest | 360.18M | 362.50M | 441.17M | 410.49M |
| StockholdersEquity | 360.18M | 362.50M | 441.17M | 410.49M |
| GainsLossesNotAffectingRetainedEarnings | -5.50M | -5.47M | -2.43M | -3.17M |
| OtherEquityAdjustments | -5.50M | -5.47M | -2.43M | -3.17M |
| RetainedEarnings | -1.15B | -985.50M | -778.46M | -685.93M |
| AdditionalPaidInCapital | 1.52B | 1.35B | 1.22B | 1.10B |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 880.61M | 783.63M | 750.48M | 729.00M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 124.23M | 604.52M | 591.70M | 586.40M |
| OtherNonCurrentLiabilities | 18.00K | 18.00K | 148.00K | 166.00K |
| EmployeeBenefits | 6.94M | 8.26M | 4.40M | 4.54M |
| NonCurrentDeferredLiabilities | 0.00 | 2.88M | 6.48M | |
| NonCurrentDeferredRevenue | 0.00 | 2.88M | 6.48M | |
| LongTermDebtAndCapitalLeaseObligation | 117.27M | 596.24M | 584.27M | 575.21M |
| LongTermCapitalLeaseObligation | 19.97M | 27.42M | 18.76M | 13.00M |
| LongTermDebt | 97.30M | 568.82M | 565.51M | 562.22M |
| CurrentLiabilities | 756.38M | 179.12M | 158.78M | 142.60M |
| CurrentDeferredLiabilities | 14.22M | 16.22M | 18.03M | 17.76M |
| CurrentDeferredRevenue | 14.22M | 16.22M | 18.03M | 17.76M |
| CurrentDebtAndCapitalLeaseObligation | 566.08M | 8.32M | ||
| CurrentCapitalLeaseObligation | 7.92M | 8.32M | ||
| CurrentDebt | 558.16M | |||
| OtherCurrentBorrowings | 558.16M | |||
| PayablesAndAccruedExpenses | 176.07M | 154.57M | 140.75M | 124.84M |
| CurrentAccruedExpenses | 70.98M | 60.18M | 55.55M | 52.24M |
| Payables | 105.09M | 94.39M | 85.20M | 72.60M |
| AccountsPayable | 105.09M | 94.39M | 85.20M | 72.60M |
| TotalAssets | 1.24B | 1.15B | 1.19B | 1.14B |
| TotalNonCurrentAssets | 134.21M | 111.72M | 80.12M | 65.97M |
| OtherNonCurrentAssets | 14.62M | 14.02M | 11.16M | 12.09M |
| NetPPE | 119.59M | 97.70M | 68.96M | 53.88M |
| AccumulatedDepreciation | -58.41M | -54.81M | -47.64M | -42.96M |
| GrossPPE | 178.00M | 152.51M | 116.60M | 96.84M |
| Leases | 12.13M | 11.70M | 9.35M | 7.08M |
| OtherProperties | 84.49M | 80.71M | 63.84M | 54.43M |
| MachineryFurnitureEquipment | 46.85M | 35.41M | 27.43M | 24.18M |
| LandAndImprovements | 34.53M | 24.70M | 15.99M | 11.15M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.11B | 1.03B | 1.11B | 1.07B |
| RestrictedCash | 2.33M | 1.74M | 508.00K | 807.00K |
| PrepaidAssets | 7.22M | 6.78M | 6.20M | 4.71M |
| Inventory | 35.09M | 38.15M | 29.38M | 24.43M |
| FinishedGoods | 23.11M | 18.09M | 15.74M | 14.67M |
| WorkInProcess | 7.97M | 9.80M | 9.32M | 8.27M |
| RawMaterials | 4.00M | 10.27M | 4.31M | 1.49M |
| Receivables | 102.07M | 77.11M | 106.03M | 105.88M |
| OtherReceivables | 27.85M | 15.89M | 19.76M | 12.31M |
| AccountsReceivable | 74.23M | 61.22M | 86.26M | 93.57M |
| CashCashEquivalentsAndShortTermInvestments | 959.87M | 910.62M | 969.42M | 937.70M |
| OtherShortTermInvestments | 796.11M | 669.79M | 854.10M | 728.90M |
| CashAndCashEquivalents | 163.77M | 240.82M | 115.33M | 208.80M |
| CashEquivalents | 151.92M | 230.87M | 105.63M | 205.66M |
| CashFinancial | 11.85M | 9.96M | 9.70M | 3.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -69.22M | -100.43M | 9.43M | 58.59M |
| RepaymentOfDebt | -12.91M | -10.00K | -28.00K | -26.00K |
| IssuanceOfDebt | 96.92M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 4.15M | 4.42M | 5.22M | 4.55M |
| CapitalExpenditure | -42.85M | -27.09M | -21.36M | -24.17M |
| InterestPaidSupplementalData | 7.71M | 6.00K | 41.00K | 101.00K |
| IncomeTaxPaidSupplementalData | 23.46M | 13.66M | 5.48M | 3.11M |
| EndCashPosition | 166.09M | 242.56M | 115.83M | 209.61M |
| BeginningCashPosition | 242.56M | 115.83M | 209.61M | 246.17M |
| EffectOfExchangeRateChanges | -174.00K | 131.00K | -97.00K | -188.00K |
| ChangesInCash | -76.30M | 126.60M | -93.68M | -36.38M |
| FinancingCashFlow | 90.31M | 15.79M | 15.49M | 25.70M |
| CashFlowFromContinuingFinancingActivities | 90.31M | 15.79M | 15.49M | 25.70M |
| ProceedsFromStockOptionExercised | 2.16M | 11.38M | 10.29M | 21.18M |
| NetCommonStockIssuance | 4.15M | 4.42M | 5.22M | 4.55M |
| CommonStockIssuance | 4.15M | 4.42M | 5.22M | 4.55M |
| NetIssuancePaymentsOfDebt | 84.01M | -10.00K | -28.00K | -26.00K |
| NetLongTermDebtIssuance | 84.01M | -10.00K | -28.00K | -26.00K |
| LongTermDebtPayments | -12.91M | -10.00K | -28.00K | -26.00K |
| LongTermDebtIssuance | 96.92M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | -140.24M | 184.15M | -139.96M | -144.83M |
| CashFlowFromContinuingInvestingActivities | -140.24M | 184.15M | -139.96M | -144.83M |
| NetInvestmentPurchaseAndSale | -97.39M | 211.24M | -118.60M | -120.66M |
| SaleOfInvestment | 778.00M | 1.21B | 1.18B | 958.00M |
| PurchaseOfInvestment | -875.39M | -1.00B | -1.30B | -1.08B |
| NetPPEPurchaseAndSale | -42.85M | -27.09M | -21.36M | -24.17M |
| PurchaseOfPPE | -42.85M | -27.09M | -21.36M | -24.17M |
| OperatingCashFlow | -26.37M | -73.34M | 30.79M | 82.76M |
| CashFlowFromContinuingOperatingActivities | -26.37M | -73.34M | 30.79M | 82.76M |
| ChangeInWorkingCapital | -3.65M | 29.66M | 11.80M | 29.07M |
| ChangeInOtherCurrentLiabilities | -6.36M | -9.78M | -7.77M | -10.98M |
| ChangeInOtherCurrentAssets | 7.39M | 4.07M | 7.11M | 4.52M |
| ChangeInPayablesAndAccruedExpense | 19.11M | 14.87M | 14.26M | 27.78M |
| ChangeInInventory | 2.57M | -8.92M | -4.34M | 2.48M |
| ChangeInReceivables | -26.36M | 29.41M | 2.55M | 5.27M |
| ChangesInAccountReceivables | -26.36M | 29.41M | 2.55M | 5.27M |
| OtherNonCashItems | -651.00K | -95.00K | -2.22M | -94.00K |
| StockBasedCompensation | 160.03M | 115.61M | 106.95M | 94.90M |
| AssetImpairmentCharge | 1.16M | 493.00K | 955.00K | 649.00K |
| AmortizationOfSecurities | -25.64M | -23.08M | -1.54M | 3.10M |
| DepreciationAmortizationDepletion | 11.23M | 10.97M | 10.62M | 10.25M |
| DepreciationAndAmortization | 11.23M | 10.97M | 10.62M | 10.25M |
| OperatingGainsLosses | -227.00K | 161.00K | -3.26M | 3.23M |
| NetForeignCurrencyExchangeGainLoss | -227.00K | 161.00K | -3.26M | 3.23M |
| NetIncomeFromContinuingOperations | -168.63M | -207.04M | -92.53M | -58.35M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NVCR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|